ENTITY
Shanghai Fudan Zhangjiang H

Shanghai Fudan Zhangjiang H (1349 HK)

49
Analysis
Health CareChina
Shanghai Fudan-Zhangjiang Bio-pharmaceutical Company Limited researches, develops, and sells self-developed bio-pharmaceutical know-how. The Company also carries out contracted research for customers, manufactures and sells diagnostic reagent, and provides related ancillary services in China.
more
Refresh
bullishAnt Group
29 Oct 2020 09:36

Ant Group IPO:  STAR Market Trading Stats, A/H Spread

Ant Group aims to raise around USD 35bn via a dual listing on HKEX and STAR board. In this note, we will look at past STAR market IPOs, their...

Share
bearishEvergrande Auto
28 Sep 2020 16:36

Evergrande Auto (708 HK): EGM Ahead Of Star Market Listing

This week in StubWorld ... Three days after raising HK$4bn via a top-up placement, Evergrande Auto (708 HK) ("EA") also officially known...

Logo
286 Views
Share
22 Jul 2018 16:09

Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation

Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...

Logo
738 Views
Share
17 Sep 2023 10:10

A-H Premium Weekly (Sep 15th): Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec Oilfield

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec...

Logo
443 Views
Share
x